Novo Nordisk A/s

Novozymes A/s

Helle Fabricius Wöldike

Christine Bruun Schiødt

Xin Zhao

Jing Su

Bernd Peschke

Tove Christensen

Florencio Zaragoza Dörwald

Esper Boel

Yun Liu

Anne Worsaae

Jianhui Deng

The present invention relates to a novel non-pathogenic() B BL21 strain comprising a deletion of group II capsular gene cluster, and the use thereof for the production of peptides.

[object Object]

The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules.

IL-21 derivatives and variants

Plasmid comprising a DNA tag encoding a peptide tag of the sequence MX(XX)wherein Xrepresents K, R or H; Xrepresents A, G, H, M, S or T; Xrepresents K, R, H, A, Q or V; n represents an integer of 1 or larger; and wherein said DNA is operably-linked to a promoter sequence are provided.

A process for expression of a protein product inis disclosed. The process comprises transformingwith a vector system comprising DNA-sequences encoding functions facilitating gene expression, a suitable marker for selection of transformants, and a DNA-sequence encoding the desired protein product. The process enables industrial production of many different polypeptides and proteins in. Examples of such products are chymosin or prochymosin other rennets, proteases, lipases and amylases. Also disclosed is an effective promoter for expression of a protein in. A preferred promoter is the TAKA-amylase promoter or functional parts thereof. There is also provided a process for the production of a recombinantlipase. The recombinantlipase fromdiffers from the native lipase in having a greater glycosylation and in exhibiting an improved thermostability.

Process for the production of protein products in aspergillus

Growing community of inventors

Måløv, Denmark

Helle Fabricius Wöldike